BASi (Bioanalytical Systems Inc.) is expanding its drug discovery and development services capabilities. The company has renovated space at its preclinical toxicology site in Evansville, IN and will relocate some research services to West Lafayette, IN, creating several new positions. BASi also has added research instrumentation at its bioanalytical labs at three sites.

The company is using proceeds from a $5.5 million public offering to make the improvements and purchase lab equipment. The building renovations in Evansville will provide scientists with more space for multiple studies.

BASi is relocating its in vivo discovery services in 2012 to its facility in the Purdue Research Park of West Lafayette, which will create several new positions. These studies will provide information clients need to evaluate new compounds in the earliest stages of development.

General manager John Devine Jr., BS, DABT, has been promoted to vice president of non-clinical services to oversee expansion of the in vivo discovery services business.

“John has successfully developed the toxicology service at Evansville consistently growing the business year by year,” said BASi president and chief executive Anthony S. Chilton Ph.D. “John’s focus on customers and his commitment to drive sales have contributed to the success of our contract research services.”

Several new triple quad mass spectrometry systems have been purchased and several AB SCIEX Triple Quad LC/MS/MS have been installed at the company’s labs in West Lafayette, McMinnville, OR and Warwickshire, UK.